Mylan finalizes $465 million settlement over EpiPen billing lawsuit
WASHINGTON (UPI) -- Mylan, the drug company that manufactures the anti-allergy injector EpiPen, finalized a $465 million settlement with the federal government stemming from allegations it over-billed Medicaid for the drug. The Justice Department alleged Mylan violated the False Claims Act by knowingly listing the EpiPen as a generic drug, which is subject to lower rebates under federal law, despite the fact there is no equivalent competitor to lower the price. In order to prevent states from suffering price gouging by […]
